Opening keynote presentation: PD-1 antibodies are transforming cancer treatments both as mono and combination therapies

PD-1 monotherapy has shown broad activity across tumor types and lines of therapy

• Precision medicine tools have been deployed to enrich monotherapy studies and to inform combination therapies
• PD-1 antibodies in combination are showing significant activity across tumor types and lines of therapy
• An extensive clinical database is allowing rapid evaluation of various precision medicine generated hypotheses

Roy Baynes, Senior Vice President and Head Global Clinical Development, Chief Medical Officer, Merck Sharp and Dohme